Hybridize Therapeutics focuses on developing targeted RNA-based therapies specifically designed to protect kidney function in patients suffering from acute and chronic kidney diseases. Their innovative approach utilizes kidney-targeted RNA therapeutics that are chemically modified to achieve a desired half-life and can be coupled with conjugates for precise cell type-specific delivery. This technology aims to provide high target specificity, minimizing off-target effects while effectively addressing the underlying causes of kidney diseases. The company is particularly focused on developing antisense oligonucleotides that target polyomaviruses, such as the BK and JC viruses, which can cause severe complications in immunocompromised patients, including kidney transplant recipients.

In addition to targeting viral infections, Hybridize Therapeutics is dedicated to addressing diseases related to Proximal Tubule Epithelial Cells (PTEC), which play a crucial role in kidney health. Their research aims to develop RNA therapeutics that can mitigate the effects of harmful compounds in the bloodstream, protect PTEC from damage, and prevent inflammatory and fibrotic processes that lead to kidney dysfunction. By leveraging their expertise in RNA biology and nephrology, Hybridize Therapeutics is positioned to make significant advancements in the treatment of kidney diseases, ultimately improving the quality of life for patients at risk of kidney failure.

Netherlands

Hybridize Therapeutics is a spin-off from the Leiden University Medical Center and is a therapeutic company focused on developing kidney-protecting modalities for untreated kidney diseases.

Hybridize Therapeutics

Company Details